News stories about Viveve Medical (NASDAQ:VIVE) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Viveve Medical earned a news impact score of 0.04 on Accern’s scale. Accern also gave media coverage about the company an impact score of 43.9528408047808 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

These are some of the news headlines that may have effected Accern Sentiment Analysis’s scoring:

Shares of Viveve Medical (VIVE) traded down $0.08 during midday trading on Thursday, reaching $3.75. 2,835,904 shares of the company traded hands, compared to its average volume of 261,793. The company has a market capitalization of $77.51, a price-to-earnings ratio of -1.74 and a beta of -0.79. Viveve Medical has a fifty-two week low of $3.30 and a fifty-two week high of $11.16. The company has a debt-to-equity ratio of 2.72, a quick ratio of 3.63 and a current ratio of 3.89.

Viveve Medical (NASDAQ:VIVE) last issued its earnings results on Wednesday, November 8th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.42) by ($0.08). The company had revenue of $4.07 million for the quarter, compared to the consensus estimate of $4.10 million. Viveve Medical had a negative return on equity of 275.77% and a negative net margin of 257.58%. The firm’s revenue was up 120.1% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.46) earnings per share. equities analysts anticipate that Viveve Medical will post -2.05 EPS for the current year.

A number of equities research analysts have recently commented on the stock. Mizuho assumed coverage on shares of Viveve Medical in a research note on Thursday, November 16th. They issued a “buy” rating and a $10.00 price objective on the stock. Cowen set a $11.00 price objective on shares of Viveve Medical and gave the company a “buy” rating in a research note on Monday, October 23rd. Northland Securities assumed coverage on shares of Viveve Medical in a research note on Friday, January 5th. They issued an “outperform” rating and a $8.00 price objective on the stock. ValuEngine raised shares of Viveve Medical from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Finally, Ladenburg Thalmann Financial Services reissued a “buy” rating on shares of Viveve Medical in a research note on Thursday, January 4th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Viveve Medical currently has a consensus rating of “Buy” and an average price target of $10.00.

COPYRIGHT VIOLATION NOTICE: This story was first published by Daily Political and is owned by of Daily Political. If you are reading this story on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this story can be viewed at

Viveve Medical Company Profile

Viveve Medical, Inc designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company’s, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories.

Insider Buying and Selling by Quarter for Viveve Medical (NASDAQ:VIVE)

Receive News & Ratings for Viveve Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical and related companies with's FREE daily email newsletter.